 Shares of Eton Pharmaceuticals Inc. ETON, 3.33 jumped 16.5 in premarket trading on Monday after the company said the Food and Drug Administration approved Zonisade, a seizure treatment for adults and teens older than 16 years old with epilepsy. Per a deal last year with the privately held Azurity Pharmaceuticals Inc., Eton will receive 5 million for the launch of the drug, royalties on net sales, and up to 15 million in commercial milestones for Zonisade and two other therapies included in the deal. 